Highlights Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:33:07 21/01/2026 GMT			5-day change	1st Jan Change
239.54 ^USD	+2.51%		-0.73%	+6.30%

01-16	Promising launch for Wegovy pill: Novo Nordisk shares surge in the US
01-16	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE

Highlights

01-15	Zydus Lifesciences Limited Receives Final Approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg	CI
01-12	Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Bosutinib Tablets, 400 Mg	CI
12-30	M&S launches new food range for customers on weight-loss jabs	AN
12-26	Formosa Pharmaceuticals, Inc. Receives Screening Acceptance Letter from SAHPRA for the Registration of App13007	CI
12-22	Granules India Arm Gets US FDA's Tentative Nod for Generic Amphetamine Extended-Release Tablets	MT
12-18	Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution	CI
12-11	Glenmark Pharmaceuticals to Launch Leucovorin Calcium for Injection	MT
12-10	Scienture and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli, the First FDA-Approved Ready-To-Use Oral Suspension of Losartan Potassium	CI
12-08	Halozyme Therapeutics, Inc. Announces Election of Jim Lang to Board of Directors, Effective December 4, 2025	CI
12-02	Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol	CI
12-01	Amneal Announces U.S. Fda Approval of Cyclosporine Ophthalmic Emulsion 0.05%	CI
12-01	Lupin Gets US FDA Nod for Biosimilar Armlupeg	MT
11-26	Shandong Boan Biotechnology Co., Ltd. Receives Marketing Approval for its Aflibercept Intravitreous Injection, Boyoujing	CI
11-14	Zydus Lifesciences Limited Receives Final Approval from Usfda for Leuprolide Acetate Injection, 14 Mg/2.8Ml (1 Mg/0.2 Ml) Multiple-Dose Vial	CI
11-12	Atea Pharmaceuticals, Inc. Announces Research Findings, Including Evidence of A Unique Dual Mechanism of Action for Bemnifosbuvir Against Hepatitis C Virus and the Expansion of the Company's Antiviral Pipeline with A New Hepatitis E Virus Program	CI
31/10/25	Iqvia Holdings Insider Sold Shares Worth $878,800, According to a Recent SEC Filing	MT
28/10/25	Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	CI
28/10/25	IQVIA Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
28/10/25	IQVIA Holdings Inc. Reaffirms Earnings Guidance for the Full Year 2025	CI
28/10/25	IQVIA Holdings Q3 Adjusted Earnings, Revenue Increase; 2025 Guidance Narrowed	MT
28/10/25	(IQV) IQVIA Expects Full Year 2025 Revenue Range $16.15B - $16.25B, vs. FactSet Est of $16.17B	MT
28/10/25	(IQV) IQVIA Expects Full Year 2025 Adjusted EPS Range $11.85 - $11.95, vs. FactSet Est of $11.87	MT
28/10/25	IQVIA narrows annual profit forecast amid continued research contract cancellations	RE
28/10/25	Earnings Flash (IQV) IQVIA Holdings Inc. Reports Q3 Revenue $4.10B, vs. FactSet Est of $4.08B	MT
28/10/25	Earnings Flash (IQV) IQVIA Holdings Inc. Posts Q3 Adjusted EPS $3.00 per Share, vs. FactSet Est of $2.98	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Highlights

Filters